Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

This study tests a combination of three drugs — leflunomide, pomalidomide, and dexamethasone — for multiple myeloma (a type of blood cancer) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You have been diagnosed with multiple myeloma that has relapsed (come back) or is refractory (not responding to treatment) - You have received at least two prior lines of treatment, including a proteasome inhibitor and an immunomodulatory drug - You are 18 or older and in adequate overall health (ECOG performance status 0–2) - You have measurable disease on blood or urine tests **You may NOT be eligible if...** - You have active, uncontrolled infections - You have serious liver or kidney problems - You have a history of serious blood clots without being on anticoagulation - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.